Cargando…

Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation

AIM: Vascular endothelial growth factor (VEGF) has been implicated in mediating the effect of antidepressant therapies as it plays a significant role in the neurogenesis. Anhedonia, an endophenotype of major depressive disorder (MDD), is related to the dorsolateral prefrontal cortex, the major focus...

Descripción completa

Detalles Bibliográficos
Autores principales: Elemery, Monika, Kiss, Szilvia, Dome, Peter, Pogany, Laszlo, Faludi, Gabor, Lazary, Judit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193814/
https://www.ncbi.nlm.nih.gov/pubmed/35711587
http://dx.doi.org/10.3389/fpsyt.2022.806731
_version_ 1784726558974410752
author Elemery, Monika
Kiss, Szilvia
Dome, Peter
Pogany, Laszlo
Faludi, Gabor
Lazary, Judit
author_facet Elemery, Monika
Kiss, Szilvia
Dome, Peter
Pogany, Laszlo
Faludi, Gabor
Lazary, Judit
author_sort Elemery, Monika
collection PubMed
description AIM: Vascular endothelial growth factor (VEGF) has been implicated in mediating the effect of antidepressant therapies as it plays a significant role in the neurogenesis. Anhedonia, an endophenotype of major depressive disorder (MDD), is related to the dorsolateral prefrontal cortex, the major focus of brain stimulation in MDD. The aim of our study was to analyze the change of serum VEGF level after rTMS treatment in association with anhedonia. MATERIALS AND METHODS: A dataset of 17 patients with TRD who were treated with antidepressants and bilateral rTMS for 2 × 5 days was analyzed. Depression was measured by the Montgomery–Asberg Depression Scale (MADRS) and anhedonia by the Snaith–Hamilton Pleasure Scale (SHAPS) for monitoring the symptom changes. The serum VEGF levels and symptoms were assessed on the first (V1), on the 14th (V2), and on the 28th day (V3). The level of VEGF was measured by ELISA assay. RESULTS: There was no significant association between MADRS scores and serum VEGF levels at any timepoint. The decrease in the SHAPS score was significantly associated with the increase in VEGF level between V1 and V2 (p = 0.001). The VEGF levels were significantly higher in non-responders than in responders (p = 0.04). The baseline VEGF level has been proven as a significant predictor of treatment response (p = 0.045). CONCLUSION: Our results suggest that serum VEGF can be sensitive to the changes of anhedonia during rTMS treatment. Considering that the most widely used depression scales are not applicable for the assessment of anhedonia, measurement of anhedonia in rTMS treatment studies of patients with TRD can be suggested as more appropriate data on distinct pathogenic pathways and specific biomarkers of the disorder.
format Online
Article
Text
id pubmed-9193814
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91938142022-06-15 Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation Elemery, Monika Kiss, Szilvia Dome, Peter Pogany, Laszlo Faludi, Gabor Lazary, Judit Front Psychiatry Psychiatry AIM: Vascular endothelial growth factor (VEGF) has been implicated in mediating the effect of antidepressant therapies as it plays a significant role in the neurogenesis. Anhedonia, an endophenotype of major depressive disorder (MDD), is related to the dorsolateral prefrontal cortex, the major focus of brain stimulation in MDD. The aim of our study was to analyze the change of serum VEGF level after rTMS treatment in association with anhedonia. MATERIALS AND METHODS: A dataset of 17 patients with TRD who were treated with antidepressants and bilateral rTMS for 2 × 5 days was analyzed. Depression was measured by the Montgomery–Asberg Depression Scale (MADRS) and anhedonia by the Snaith–Hamilton Pleasure Scale (SHAPS) for monitoring the symptom changes. The serum VEGF levels and symptoms were assessed on the first (V1), on the 14th (V2), and on the 28th day (V3). The level of VEGF was measured by ELISA assay. RESULTS: There was no significant association between MADRS scores and serum VEGF levels at any timepoint. The decrease in the SHAPS score was significantly associated with the increase in VEGF level between V1 and V2 (p = 0.001). The VEGF levels were significantly higher in non-responders than in responders (p = 0.04). The baseline VEGF level has been proven as a significant predictor of treatment response (p = 0.045). CONCLUSION: Our results suggest that serum VEGF can be sensitive to the changes of anhedonia during rTMS treatment. Considering that the most widely used depression scales are not applicable for the assessment of anhedonia, measurement of anhedonia in rTMS treatment studies of patients with TRD can be suggested as more appropriate data on distinct pathogenic pathways and specific biomarkers of the disorder. Frontiers Media S.A. 2022-05-31 /pmc/articles/PMC9193814/ /pubmed/35711587 http://dx.doi.org/10.3389/fpsyt.2022.806731 Text en Copyright © 2022 Elemery, Kiss, Dome, Pogany, Faludi and Lazary. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Elemery, Monika
Kiss, Szilvia
Dome, Peter
Pogany, Laszlo
Faludi, Gabor
Lazary, Judit
Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation
title Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation
title_full Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation
title_fullStr Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation
title_full_unstemmed Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation
title_short Change of Circulating Vascular Endothelial Growth Factor Level and Reduction of Anhedonia Are Associated in Patients With Major Depressive Disorder Treated With Repetitive Transcranial Magnetic Stimulation
title_sort change of circulating vascular endothelial growth factor level and reduction of anhedonia are associated in patients with major depressive disorder treated with repetitive transcranial magnetic stimulation
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193814/
https://www.ncbi.nlm.nih.gov/pubmed/35711587
http://dx.doi.org/10.3389/fpsyt.2022.806731
work_keys_str_mv AT elemerymonika changeofcirculatingvascularendothelialgrowthfactorlevelandreductionofanhedoniaareassociatedinpatientswithmajordepressivedisordertreatedwithrepetitivetranscranialmagneticstimulation
AT kissszilvia changeofcirculatingvascularendothelialgrowthfactorlevelandreductionofanhedoniaareassociatedinpatientswithmajordepressivedisordertreatedwithrepetitivetranscranialmagneticstimulation
AT domepeter changeofcirculatingvascularendothelialgrowthfactorlevelandreductionofanhedoniaareassociatedinpatientswithmajordepressivedisordertreatedwithrepetitivetranscranialmagneticstimulation
AT poganylaszlo changeofcirculatingvascularendothelialgrowthfactorlevelandreductionofanhedoniaareassociatedinpatientswithmajordepressivedisordertreatedwithrepetitivetranscranialmagneticstimulation
AT faludigabor changeofcirculatingvascularendothelialgrowthfactorlevelandreductionofanhedoniaareassociatedinpatientswithmajordepressivedisordertreatedwithrepetitivetranscranialmagneticstimulation
AT lazaryjudit changeofcirculatingvascularendothelialgrowthfactorlevelandreductionofanhedoniaareassociatedinpatientswithmajordepressivedisordertreatedwithrepetitivetranscranialmagneticstimulation